scholarly journals Clinical Outcome in Soft Tissue Sarcoma Patients with Lung Metastasis Who Received Metastasectomy and/or Radiofrequency Ablation: Tokai Musculoskeletal Oncology Consortium Study

2021 ◽  
Vol Volume 13 ◽  
pp. 8473-8480
Author(s):  
Tomoki Nakamura ◽  
Kunihiro Asanuma ◽  
Motoshi Takao ◽  
Takashi Yamanaka ◽  
Hiroshi Koike ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Clinical Outcome ◽  
Lung Metastasis ◽  
Musculoskeletal Oncology

scholarly journals The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study

Cancer ◽  
2016 ◽  
Vol 122 (9) ◽  
pp. 1408-1416 ◽  
Author(s):  
Tomoki Nakamura ◽  
Akihiko Matsumine ◽  
Akira Kawai ◽  
Nobuhito Araki ◽  
Takahiro Goto ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Clinical Outcome ◽  
Japanese Patients ◽  
Oncology Group ◽  
Musculoskeletal Oncology

scholarly journals Immune classification of soft tissue sarcoma predicts clinical outcome

2019 ◽  
Vol 30 ◽  
pp. v689 ◽  
Author(s):  
F. Petitprez ◽  
A. de Reyniès ◽  
E.Z. Keung ◽  
T W-W Chen ◽  
C.-M. Sun ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Clinical Outcome

Efficacy and safety of trabectedin for patients with unresectable and relapsed soft‐tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study

Cancer ◽  
2019 ◽  
Vol 126 (6) ◽  
pp. 1253-1263 ◽  
Author(s):  
Hiroshi Kobayashi ◽  
Shintaro Iwata ◽  
Toru Wakamatsu ◽  
Keiko Hayakawa ◽  
Tsukasa Yonemoto ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Efficacy And Safety ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Musculoskeletal Oncology

Combination of Gemcitabine and Docetaxel in Management of Leiomyosarcoma Metastasis

2017 ◽  
Vol 1 (2) ◽  
pp. AY1-AY2
Author(s):  
Monali Rajawat
Keyword(s):  
Small Intestine ◽  
Radiofrequency Ablation ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Combination Therapy ◽  
Genetic Factors ◽  
Target Therapy ◽  
Treatment Options ◽  
Main Route

Leiomyosarcoma is a type of a soft tissue sarcoma which is one of the rarest tumor found in the human mankind. It is predominantly localized either in stomach, small intestine or retroperitoneum and often metastasizes to the distant parts like the lungs or liver. The main route of the metastasis is via the bloodstream, however, the lymphatics could also be used as a medium. The etiology of leiomyosarcoma (LMS) is yet unknown to men, but few studies has shown that genetic factors have an important role to play. The treatment options available for LMS metastasis (mets) in liver are very limited which ranges from chemotherapy, radiofrequency ablation and target therapy. Here I discuss a case of LMS mets to the liver managed by a combination therapy of Gemcitabine and Docetaxel.

scholarly journals Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan

2020 ◽  
Vol Volume 14 ◽  
pp. 4215-4220
Author(s):  
Tomoki Nakamura ◽  
Kunihiro Asanuma ◽  
Tomohito Hagi ◽  
Akihiro Sudo
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Clinical Outcome ◽  
Systemic Treatment ◽  
Real Life ◽  
Advanced Soft Tissue Sarcoma

scholarly journals A molecular signature predictive of clinical outcome following pazopanib therapy in advanced soft tissue sarcoma

2017 ◽  
Vol 28 ◽  
pp. x149
Author(s):  
P. Huang ◽  
A. Lee ◽  
F. McCarthy ◽  
K. Thway ◽  
J. Morden ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Clinical Outcome ◽  
Molecular Signature ◽  
Advanced Soft Tissue Sarcoma
Sign in / Sign up

Export Citation Format

Share Document